Patrick J Morris

List of Publications by Citations

33 papers	2,678 citations	21 h-index	39 g-index
39 ext. papers	3,506 ext. citations	12.9 avg, IF	4.94 L-index

#	Paper	IF	Citations
33	NMDAR inhibition-independent antidepressant actions of ketamine metabolites. *Nature*, **2016**, 533, 481-6	50.4	903
32	Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. *Pharmacological Reviews*, **2018**, 70, 621-660	22.5	395
31	Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. *Nature*, **2017**, 549, 533-537	50.4	185
30	Palladium-catalyzed diastereo- and enantioselective synthesis of substituted cyclopentanes through a dynamic kinetic asymmetric formal [3+2]-cycloaddition of vinyl cyclopropanes and alkylidene azlactones. *Angewandte Chemie - International Edition*, **2011**, 50, 6167-70	16.4	183
29	Palladium-catalyzed diastereo- and enantioselective formal [3 + 2]-cycloadditions of substituted vinylcyclopropanes. *Journal of the American Chemical Society*, **2012**, 134, 17823-31	16.4	142
28	Antidepressant-relevant concentrations of the ketamine metabolite (2,6)-hydroxynorketamine do not block NMDA receptor function. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 5160-5169	11.5	77
27	()-hydroxynorketamine exerts mGlu receptor-dependent antidepressant actions. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 6441-6450	11.5	73
26	The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection. *PLoS Neglected Tropical Diseases*, **2017**, 11, e0005540	4.8	67
25	High-potency ligands for DREADD imaging and activation in rodents and monkeys. *Nature Communications*, **2019**, 10, 4627	17.4	64
24	Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. *Science Translational Medicine*, **2019**, 11,	17.5	64
23	Palladium-Catalyzed Diastereo- and Enantioselective Synthesis of Substituted Cyclopentanes through a Dynamic Kinetic Asymmetric Formal [3+2]-Cycloaddition of Vinyl Cyclopropanes and Alkylidene Azlactones. *Angewandte Chemie*, **2011**, 123, 6291-6294	3.6	63
22	Organophosphorus flame retardants inhibit specific liver carboxylesterases and cause serum hypertriglyceridemia. *ACS Chemical Biology*, **2014**, 9, 1097-103	4.9	54
21	Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects. *Psychopharmacology*, **2018**, 235, 3017-3030	4.7	53
20	(R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses. *British Journal of Pharmacology*, **2019**, 176, 2573-2592	8.6	38
19	Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell Cultures. *Journal of Infectious Diseases*, **2018**, 218, S672-S678	7	38
18	Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites. *Organic Letters*, **2017**, 19, 4572-4575	6.2	38
17	Metabolic profiling reveals PAFAH1B3 as a critical driver of breast cancer pathogenicity. *Chemistry and Biology*, **2014**, 21, 831-40		35

16	Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. *Molecular Psychiatry*, **2021**,	15.1	32
15	Discovery and in Vivo Evaluation of Potent Dual CYP11B2 (Aldosterone Synthase) and CYP11B1 Inhibitors. *ACS Medicinal Chemistry Letters*, **2013**, 4, 1203-7	4.3	29
14	Multidimensional profiling platforms reveal metabolic dysregulation caused by organophosphorus pesticides. *ACS Chemical Biology*, **2014**, 9, 423-32	4.9	24
13	Zanos et al. reply. *Nature*, **2017**, 546, E4-E5	50.4	21
12	Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of ()-hydroxynorketamine. *Journal of Psychopharmacology*, **2019**, 33, 12-24	4.6	21
11	Reply to: Antidepressant Actions of Ketamine Versus Hydroxynorketamine. *Biological Psychiatry*, **2017**, 81, e69-e71	7.9	20
10	Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications. *Pharmacological Reviews*, **2021**, 73, 763-791	22.5	17
9	miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. *Journal of Experimental Medicine*, **2018**, 215, 2115-2136	16.6	14
8	Chemical genetics screening reveals KIAA1363 as a cytokine-lowering target. *ACS Chemical Biology*, **2014**, 9, 2905-13	4.9	8
7	F-labeled radiotracers for in vivo imaging of DREADD with positron emission tomography. *European Journal of Medicinal Chemistry*, **2021**, 213, 113047	6.8	5
6	Apilimod. *IUCrData*, **2017**, 2,	0.7	4
5	A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801. *Neurotoxicology and Teratology*, **2021**, 87, 106993	3.9	4
4	Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In Vivo. *Microorganisms*, **2021**, 9,	4.9	3
3	Hydroxynorketamine Pharmacokinetics and Antidepressant Behavioral Effects of (26)- and (5)-Methyl-(26)-hydroxynorketamines.. *ACS Chemical Neuroscience*, **2022**,	5.7	1
2	Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration.. *Translational Psychiatry*, **2022**, 12, 179	8.6	1
1	Time will tell. Reply to "Comments to pharmacological and behavioral divergence of ketamine enantiomers by Jordi Bonaventura et al." by Chen et al.. *Molecular Psychiatry*, **2022**,	15.1	0